JTO Clinical and Research Reports (Jan 2024)

The First Case Report of Effective Treatment With Sotorasib for Metastatic Atypical Lung Carcinoid Harboring KRAS G12C Mutation and Aggressive Disseminated Lung Metastasis: A Case Report

  • Masafumi Saiki, MD,
  • Chisa Omori, MD,
  • Honami Morikawa, MD,
  • Ken Shinohara, MD,
  • So Shimamura, MD,
  • Hiroki Ohkoshi, MD,
  • Yoshinori Uchida, MD,
  • Tomohiro Inoue, MD, PhD,
  • Tetsuo Kondo, MD, PhD,
  • Shinnosuke Ikemura, MD, PhD,
  • Kenzo Soejima, MD, PhD

Journal volume & issue
Vol. 5, no. 1
p. 100620

Abstract

Read online

Pulmonary neuroendocrine tumors are rare, accounting for approximately 1% to 2% of lung cancers. Atypical carcinoids account for approximately 10% of pulmonary neuroendocrine tumors and are categorized as moderately malignant. Treatment options for advanced-stage atypical carcinoids include everolimus, cytotoxic anticancer agents, and peptide receptor radionuclide therapy. In this report, we present the first case of KRAS G12C mutation-positive atypical carcinoid that was successfully treated with sotorasib. Therapeutically important mutations observed in non-small cell lung cancer are seldom found in atypical carcinoid tumors. Nonetheless, it is worthwhile to search for genetic mutations in atypical carcinoid tumors, considering the potential for molecular targeted therapy to be effective in their treatment as well.

Keywords